Utilization of antipsychotic medications in the youth population of Manitoba: 1996-2011
Serious safety concerns have been raised recently about the use of second generation antipsychotics (SGAs), in young patients. In this population based study, utilization of antipsychotics use in the youth population of Manitoba between 1996 and 2011 was determined. Rates of adverse events (diabetes, hypertension, EPS) were compared among the users of SGAs. School enrolment and high school completion rates were evaluated for young users. Databases from the Population Health Research Data Repository, housed at the Manitoba Centre of Health Policy were accessed. Increased utilization (prevalence: 2.3 to 9 per 1,000 persons; incidence: 1.2 to 2.7 per 1,000 between 2001 and 2011) of SGAs was observed in the youth population of MB. The most common diagnosis recorded were Attention Deficit Hyperactivity Disorder (56.8%), Conduct Disorders (38%) and Mood Disorders (22.7%). Olanzapine therapy seemed to be associated with a higher risk of hypertension compared to risperidone users (HR: 2.52, 95% CI: 1.20 – 5.29). Risperidone users seemed to be at higher risk of EPS than quetiapine users (HR: 0.46, 95% CI: 0.26 – 0.82). School enrolment of SGAs users appeared to be comparable to those reported for the general population. High school completion rates may be lower than those of the general population.
Pharmacoepidemiology, Antipsychotics, Children and Adolescents